Jun. 23 at 8:33 PM
$SGMO For what’s its worth… feel for the longs that lost life savings in Sangamo!
We’d love for you to take a look at
$PLX. Our partners Chiesi and Pfizer commercialized PLXs two approved lysosomal treatments. Sales are growing for Elfabrio and label expansion in EMA should continue to elevate sales. FDA expansion should be next. Our comparator trial has skewed data points because all our patients were stage 3-4 CKD who must swing over from Fabrazyme, eg, patients were on the downhill slope of things, but we met endpoints. The other two P3s had stellar eGFR, 40xs high life, virtually wiped out ADA’s, patients started to sweat again. In 2025 FDA scope.. ELFABRIO had 0 DEATHS with 4 minor adverse events like nausea; reason being.. it actually works! Just a matter of time before it sell 2b a year ;)
